Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis

This publication has 8 references indexed in Scilit:

• Anti-tumour necrosis factor treatment with infliximab in a case of giant cell arteritis resistant to steroid and immunosuppressive drugs
  Rheumatology, 2002
• Treatment of longstanding active giant cell arteritis with infliximab: Report of four cases
  Arthritis & Rheumatism, 2001
• Effect of infliximab on sight-threatening panuveitis in Behcet's disease
  The Lancet, 2001
• Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms
  Arthritis & Rheumatism, 2000
• Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab
  Arthritis & Rheumatism, 2000
• Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
  The Lancet, 1999
• Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica
  Arthritis & Rheumatism, 1997
• Immuno-localisation of tumour necrosis factor and its receptors in temporal arteritis
  Rheumatology International, 1997